Please login or register to print this page.

ARTICLE CONTRIBUTORS

European Society of Cardiology

Clinical Articles, Lead Article

ESC Heart Failure Guidelines – devices, drugs and diagnosis

New recommendations1 on devices, drugs and diagnosis in heart failure were launched at the Heart Failure Congress 2012, held in Belgrade, Serbia, and published recently in the European Heart Journal.

An analysis of the clinical evidence on heart failure by the ESC Guidelines task force led to several major updates since the previous ESC Guidelines were published in 2008. The ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 were developed by the European Society of Cardiology (ESC) in collaboration with the Heart Failure Association (HFA) of the ESC.

A new indication for cardiac resynchronisation therapy (CRT) in patients with mild symptoms is given in the guidelines. More evidence from new trials and further analysis of existing trials also enabled the task force to provide more clarity about the effects of CRT. It is clear that patients with left bundle branch block QRS morphology and those who are in sinus rhythm have the greatest benefit from CRT, they say. Conversely, those who have a non-left bundle branch block QRS morphology and patients in atrial fibrillation have less certain benefit.

Professor John McMurray

Professor John McMurray

Also in the device arena, new transcatheter valve interventions are discussed. “These interventions offer the possibility of treating aortic stenosis in patients who are unsuitable for surgery,” says Professor John McMurray (Glasgow, UK), chairperson of the ESC Clinical Practice Guidelines Task Force.

In pharmacological treatments, two new indications are highlighted.  The guidelines stress that when attempting to reduce heart rate, the dose of beta blocker should be maximised before giving additional medications to reduce heart rate. “Beta blockers are more established, more effective and less expensive, and should be given first,” says Professor McMurray.

New evidence has extended the indication for mineralocorticoid receptor antagonists (aldosterone antagonists). This means that for many patients, standard therapy should include three neurohumoral antagonists – an angiotensin converting enzyme inhibitor (or angiotensin receptor blocker), a beta blocker and, if symptoms persist, now a mineralocorticoid receptor antagonist as well.

In the area of diagnostics, a new biomarker called mid-regional pro-A-type natriuretic peptide is mentioned for the first time.

Professor McMurray concludes: “These guidelines make recommendations based upon evidence for established and new diagnostic tests and therapies for heart failure. If implemented, they offer a real opportunity to improve the outcome of patients with this condition.”

References
1. The full guidelines are available at: http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages/acute-chronic-heart-failure.aspx

Published on: May 24, 2012

Members Area

Log in or Register now.

 For healthcare professionals only
Learning sky

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.